FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 1995 WARNER-LAMBERT COMPANY (Exact name of registrant as specified in its charter) Delaware 1-3608 22-1598912 (State or other (Commission (IRS Employer Jurisdiction of File Number) Identification incorporation) No.) 201 Tabor Road, Morris Plains, New Jersey 07950 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (201) 540-2000 Item 5. Other Events. On December 19, 1995, the Registrant issued a press release announcing the signing of a letter of intent (i) to purchase Glaxo Wellcome plc's interest in the Warner-Wellcome over-the- counter joint venture (formed in 1993 with Wellcome plc) for a purchase price of $1.05 billion and (ii) to restructure Warner- Lambert's joint venture arrangements with Glaxo Wellcome to market Glaxo Wellcome's Rx to OTC switch products, which will now include Wellcome's Rx to OTC products. The transactions are subject to completion of a final agreement and the receipt of necessary regulatory approvals. A definitive agreement is anticipated to be executed in the first half of 1996. The foregoing summary of the attached press release is qualified in its entirety by the complete text of such document, a copy of which is attached hereto. Item 7. Financial Statements, Pro Form Financial Information and Exhibits. (c) Exhibits (99) Additional Exhibits (99)(a) Press Release dated December 19, 1995. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WARNER-LAMBERT COMPANY (Registrant) Date: December 19, 1995 By: ERNEST J. LARINI Vice President and Chief Financial Officer Exhibit Index Exhibit No. Exhibit Page No. (99)(a) Press release of the Registrant dated December 19, 1995